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A B S T R A C T
HER2-targeted monoclonal antibodies improve the outcome for advanced breast cancer patients; however, re-
sistance to therapy is still frequent. Epitope masking and steric hindrance to antibody binding through matrix
components are thought to be the major mechanism. We asked whether tumors resistant to trastuzumab can still
be eliminated by CAR T cells redirected by the same antibody domain. While saturating doses of trastuzumab in
the presence of CD16.176V.NK-92 effector cells and trastuzumab derived CAR T cells equally well recognized
and killed HER2-positive tumor cells in a monolayer, only CAR T cells penetrated into the core region of tumor
spheroids and exhibited cytotoxic activity in vitro, whereas antibodies failed. In NSG mice treatment with
trastuzumab and CD16.176V.NK-92 cells only transiently retarded tumor growth but did not induce regression
of clinically trastuzumab-resistant breast cancer xenografts. In contrast, one dose of HER2-specific CAR T cells
eradicated established tumors resulting in long-term survival. Data indicate that CAR T cells can successfully
combat antibody resistant tumors by targeting the same epitope suggesting that CAR T cells can penetrate the
tumor matrix which is a barrier for antibodies.
1. Introduction
Human epidermal growth factor receptor-2 (HER2)-specific mono-
clonal antibody therapies revolutionized treatment of HER2-positive
breast cancer since the FDA approved the first of their kind, trastu-
zumab (Herceptin®), in 1998 [1]. Recent clinical studies show that the
combination of pertuzumab, trastuzumab and docetaxel further im-
proves progression free and overall survival [2]. However, a great
percentage of patients still fail to respond to therapy or experience
tumor relapse despite initial regression and persistent antigen expres-
sion [3]. The most intensively studied general mechanisms of trastu-
zumab resistance are obstacles for trastuzumab binding to HER2, up-
regulation of HER2 downstream signaling pathways, signaling through
alternate pathways and failure to trigger immune-mediated mechan-
isms to destroy tumor cells [1,4]. In this manuscript we focus on
resistance to antibody therapy that occurs through epitope masking and
steric hindrance to antibody binding by extracellular matrix compo-
nents such as MUC4 or CD44/hyaluronan [5–7].
Epitope masking of HER2 is emphatic in advanced tumors of JIMT-1
xenografts [8] while trastuzumab can still bind to early stage tumors as
well as circulating and disseminated tumor cells and induce antibody
dependent cellular cytotoxicity (ADCC) [9,10]. In addition, targeting
multiple epitopes by combined treatment with pertuzumab and tras-
tuzumab further improves ADCC and recruits higher number of effector
cells, thereby delaying tumor outgrowth [11]. These results suggest that
in spite of intrinsic biological resistance of JIMT-1 cells, ADCC by NK
cells can overcome primary resistance and hinder tumor outgrowth
while the extracellular matrix is less abundant. However, at later stages
the tumors become resistant due to a massive extracellular matrix that
restricts access to antibodies [5–7].
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In contrast to passively diffusing antibodies, antibody-redirected
immune cells can actively penetrate tumors. Immune cell therapy with
adoptively transferred chimeric antigen receptor (CAR)-redirected T
cells is an engaging option to improve outcomes for patients with ad-
vanced or metastatic breast cancer [12–14]. In vitro, HER2-specific
CAR T cells recognized and efficiently killed trastuzumab sensitive
SKBR3 or BT474 breast cancer cell lines [13,15]. However, we have no
evidence for their therapeutic efficacy towards trastuzumab resistant
tumors. Clinically, HER2-redirected CAR T cells are successful in the
treatment of osteosarcoma and glioblastoma in early phase trials
[16,17]; however, none of the trial participants received HER2 tar-
geting monoclonal antibodies prior CAR T cell administration.
Here we addressed whether HER2-specific CAR T cells are effica-
cious against trastuzumab resistant, HER2+ breast tumor lesions. We
engineered T cells with a trastuzumab derived HER2-specific CAR that
binds by the same binding domain and thereby recognizes the same
epitope as trastuzumab. These T cells recognize HER2+ breast cancer
cells that are inherently resistant to trastuzumab in three dimensional
cell cultures and successfully combat large trastuzumab resistant breast
cancer xenografts that are not penetrated by trastuzumab to induce
ADCC. Data indicate that CAR T cells in contrast to antibodies can be
efficacious against antibody resistant tumors providing a significant
survival advantage.
2. Methods
Cell lines and media conditions, flow cytometry, cytokine secretion
assay, cytotoxicity assay, ex vivo tumor xenograft immunohistology,
confocal microscopy and statistical analysis are described in detail in
the supplementary methods section.
All materials were from Sigma-Aldrich (St. Louis, MO, USA) unless
otherwise indicated.
2.1. Retrovirus production and transduction of T cells
Retroviral particles were generated by transient transfection of HEK
293T cells with the CAR-encoding MSGV retroviral vector [12], Peg-
Pam-e plasmid containing the sequence for MoMLV gag-pol, and
pMEVSVg plasmid containing the sequence for VSVg, using jetPrime
transfection reagent (Polyplus, Illkirch, France). The trastuzumab de-
rived HER2-specific CAR, a kind gift from Dr. Richard A. Morgan at the
NCI, NIH, is composed of the Ig kappa chain signal peptide; trastu-
zumab light chain variable region; the 218 peptide linker; trastuzumab
heavy chain variable region; the hinge, transmembrane and cyto-
plasmic region of human CD28; and the cytoplasmic region of human
CD3 zeta [12,18]. The retroviral vector with the irrelevant, p97 (mel-
anotransferrin) specific CAR was generated in a similar fashion using
the p97-specific scFv L49. Supernatants containing the retrovirus were
collected after 48 h.
Experiments were carried out on human samples in accordance with
the Declaration of Helsinki and approved by the Regional and
Institutional Committee for Research Ethics (RKEB.5378/2019). To
generate HER2-specific CAR T cells, human peripheral blood mono-
nuclear cells were isolated by Ficoll gradient centrifugation and sti-
mulated in non-tissue culture 24-well plates precoated with 1 μg/ml
OKT3 (ThermoFischer, Waltham, MA, USA) and anti-CD28 (R&D
Systems, Minneapolis, MN, USA) antibodies. On day 2, human inter-
leukin-7 (IL7; 10 ng/ml) and human interleukin-15 (IL15; 5 ng/ml)
(Miltenyi Biotec Bergisch Gladbach, Germany) were added to cultures.
T cells were transduced with retroviral particles on RetroNectin-coated
(Takara, Kusatsu, Japan) plates on day 3 in the presence IL7 (10 ng/ml)
and IL15 (5 ng/ml). The expansion of T cells was subsequently sup-
ported with IL7 and IL15. OKT3/CD28 activated non-transduced (NT) T
cells were expanded with IL7 and IL15 using the same protocol.
Following 48 h incubation cells were used for further experiments.
2.2. Three-dimensional cell culture
JIMT-1 cells (1 × 105 cells/ml in 200 μl) were placed into 96-well
U-bottom plates. The suspensions were centrifuged at 500×g for 5 min,
and the cell pellet was mixed in a 1:2 ratio with Matrigel (BD
Biosciences, San Jose, CA, USA) and cultured for 10 days. Some
spheroids were treated with 10 μg/ml trastuzumab or 10 μg/ml Alexa
Fluor 488 conjugated trastuzumab for 24 h.
2.3. Propidium iodide incorporation assay
Cytotoxic activity of T cells and CD16.176V.NK-92 cells in three-
dimensional cell cultures was determined by propidium iodide in-
corporation assay [19]. Spheroids of equal size were cocultured with
1 × 105 effector cells in the presence or absence of 10 μg/ml trastu-
zumab. After 24 h, 3D cocultures were labeled with 1 μg/ml propidium
iodide and target cell killing was quantitatively analyzed by confocal
microscopy. A quantitative digital image processing pipeline, created in
ImageJ [20], was used to calculate specific PI incorporation of JIMT-
1 cells in the entire spheroid and in the inner core. First, we measured
the optical slice and defined two regions. Total area represented the
whole slice, the central area with a 50% radius was defined as core. PI
incorporation was determined for both regions as integrated PI fluor-
escence intensity above a common threshold in all background-cor-
rected images. Three spheroids and at least five 2-μm-thick optical
slices per sample were analyzed.
2.4. Xenograft tumors and in vivo antibody treatment
NSG (NOD.Cg-Prkdcscid/Il2rgtm1Wjl/SzJ) mice were purchased
from The Jackson Laboratory and housed in a specific-pathogen-free
environment. All animal experiments were performed in accordance
with FELASA guidelines and recommendations and DIN EN ISO 9001
standards. Each seven-week-old female NSG mouse participating in the
study was given a subcutaneous injection in both flanks, each con-
taining 3 × 106 MDA.ffLUC, MDA-HER2.ffLUC or JIMT-1 cells in 100 μl
PBS mixed with an equal volume of Matrigel (BD Biosciences, San Jose,
CA, USA) JIMT-1 tumor volumes were derived as the product of the
length, width and height. The growth of MDA.ffLUC and MDA-
HER2.ffLUC xenografts was monitored with an IVIS Spectrum CT in-
strument (PerkinElmer, Waltham, MA, USA). Before measurement,
isoflurane-anesthetized animals were injected IP with D-luciferin
(150 mg/kg). A bioluminescence image was obtained and analyzed
after 10 min using Living Image software Version 4.0 (Caliper Life
Sciences, Waltham, MA, USA). A region of interest of the same size was
drawn over the tumor region and the intensity of the signal measured as
total photons per second per square centimeter per steradian (p/s/cm2/
sr) was obtained.
The trastuzumab group was treated with 100 μg antibody i.p. In
100 μl PBS twice weekly starting with the day of tumor cell injection.
The untreated control group was injected with 100 μl PBS i.p. twice
weekly. In the CD16.176V.NK-92 group, 5 × 106 CD16.176V.NK-
92 cells were injected i.v. on the day of tumor cell injection which was
repeated every second week. The CD16.176V.NK-92 + trastuzumab
group received both of these treatments. In HER2-CAR T cell and NT T
cell groups, mice received a single dose of 5 × 106 HER2-specific CAR
or unmodified T cells i.v. on day 14 post tumor cell inoculation.
(Fig. 3A). Experiments were approved by the National Ethical Com-
mittee for Animal Research (# 5-1/2018/DEMÁB).
3. Results
As tumor models, we have used two HER2+ trastuzumab resistant
cell lines, the clinic-derived JIMT-1 and an in vitro generated MDA-MB-
468 variant, MDA-HER2, stably expressing ectopic HER2 [21]. MDA-
MB-468 (MDA for short) served as HER2-negative, SK-BR-3 and N87
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lines as HER2+, trastuzumab sensitive controls. Also, ffLUC expressing
variants of JIMT-1, MDA and MDA-HER2 were used where appropriate.
The efficacy of human T lymphocytes engineered with a trastuzumab-
derived HER2-CAR [12] was compared to ADCC mediated by trastu-
zumab through CD16.176V.NK-92 cells, a stably transfected variant of
NK-92 [22] that express the high affinity (176V) variant of the Fcγ
receptor (CD16) [23,24].
3.1. Generation of trastuzumab-derived HER2-specific human CAR T cells
and their anti-tumor function in vitro
First we asked whether CAR T cells redirected towards the same
epitope as trastuzumab can control advanced tumors where trastu-
zumab treatment fails. In order to compare the impact of CAR T cells as
living drugs with the impact of passively diffusing antibodies on tumor
eradication, we have generated human T cells that express a CAR with
an scFv binding domain derived from trastuzumab (humanized 4D5),
stalk, transmembrane and cytoplasmic regions of human CD28 and a
CD3ζ signaling domain (Fig. 1A). Mean transduction efficiency by VSVg
pseudotyped γ-retroviruses in the CD3 positive human lymphocyte
population was 60.48% as judged by flow cytometry on day 4 post
transduction (Fig. 1B Q4-2 quadrant and C). We made certain that CARs
are stably expressed and re-confirmed CAR expression on day 10
(Suppl. Fig. 1). P97 melanotransferrin specific CAR T cells served as
irrelevant controls (Fig. 1C).
To evaluate the HER2-specific CAR-redirected T cell activation we
recorded the release of IFNγ and cytotoxicity towards target cells as key
effector functions. Incubation with HER2-Fc chimera proteins or with
HER2+ target cells (MDA-HER2 or JIMT-1) induced increase in IFNγ
release by HER2-specific CAR T cells indicating T cell activation. T cells
with a CAR of irrelevant (p97) specificity or without a CAR did not
release IFNγ. In the presence of 10 μg/ml trastuzumab, CD16.176V.NK-
92 cells also recognized HER2 and were activated to secrete IFNγ
(Fig. 1D and E). There was no cytokine secretion in the absence of ef-
fector cells, target antigen (either recombinant or on the cell surface) or
trastuzumab (in the case of CD16.176V.NK-92 cells) indicating that
activation is strictly dependent on targeting the antigen.
Using cytotoxicity assays based on ffLUC activity measurements
(Fig. 1F) and real time cell impedance analysis (Suppl. Fig. 2), HER2-
targeted CAR T cells killed specifically HER2+ cells grown in
Fig. 1. Generation of trastuzumab-derived HER2-specific human CAR T cells, characterization of their targets and their in vitro anti-tumor function.
(A) Schematic diagram illustrating the modular composition of the HER2-specific CAR. (B and C) Representative flow cytometry dot-plot and summary data (HER2-
CAR T cells [n = 6] and non-transduced T cells [n = 6]). (D and E) 5 × 105 CD16.176V.NK-92 cells ± 10 μg/ml trastuzumab or HER2-CAR or NT T cells were
incubated with 1 μg/ml HER2-Fc protein (D) or cocultured with MDA-HER2 or JIMT-1 (HER2 positive) or MDA (HER2 negative) target cells in 1:1 T cell to tumor cell
ratio (E). After 24 h, IFNγ was determined in the culture supernatant by ELISA (n = 4, assay performed in duplicates). (F) firefly-Luciferase-based cytotoxicity assay
using CD16.176V.NK-92 cells ± 10 μg/ml trastuzumab or HER2-CAR or NT T cells against MDA-HER2 or JIMT-1 (HER2 positive) or MDA (HER2 negative) as targets
at 0.5:1 T cell to tumor cell ratio (n = 4; assay was performed in duplicates; Histograms show mean ± SEM; HER2-CAR or CD16.176V.NK-92+trastuzumab vs.
medium: ***p < 0.001). (G) Quantitative analysis of HER2 expression on MDA-HER2, JIMT-1 (HER2+) and MDA (HER2-) cell lines. (H) In vitro analysis of direct
growth inhibitory effect of 100 μg/ml trastuzumab on MDA (HER2-), MDA-HER2 and JIMT-1 (HER2+) trastuzumab resistant cell lines; HER2+ SKBR3 and N87
served as trastuzumab sensitive controls. (I) Cryostat sections from trastuzumab resistant MDA-HER2 (left column) and JIMT-1 (middle column) xenografts were
fluorescently labeled for HER2 (green), CD44 (red), and DNA (DAPI, blue). N87 tumors served as trastuzumab sensitive control (right column). (J) CD44 expression
was determined as integrated pixel intensity (A647 channel; intensity × area). Histograms represent the mean ± SD (n = 5; ***p < 0.001).
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monolayers, but not HER2- (MDA) target cells (p < 0.001). These data
are coherent with the pro-inflammatory activation upon CAR binding
indicated by IFNγ release (Fig. 1E). In addition, trastuzumab-engaged
CD16.176V.NK-92 cells induced HER2 specific killing of HER2+ but not
of HER2- target cells (p < 0.001). Real time analysis of killing HER2
positive target cells revealed that in the presence of saturating doses of
trastuzumab CD16.176V.NK-92 cells executed faster killing than HER2-
CAR T cells during the initial 3–4 h. However, their killing slowed down
afterwards and became less efficient while CAR T cells remained potent
killers during a period of 24 h (Suppl. Fig. 2).
We verified that native and ffLUC-transduced MDA-HER2 and JIMT-
1 cells express similar amounts of HER2 antigens (Fig. 1G and Suppl.
Fig. 3A), and are resistant to trastuzumab in vitro (Fig. 1H and Suppl.
Fig. 3B). In these assays MDA cells served as HER2-negative, N87 and
SKBR-3 cells as HER2-positive, trastuzumab sensitive controls [13,15].
We also confirmed that expression of CD44, the receptor for hyalur-
onan, a major ECM component, is significantly higher in the trastu-
zumab resistant JIMT-1 and MDA-HER2 tumor xenografts than in
trastuzumab sensitive controls (Fig. 1I and J).
3.2. HER2-CAR T cells recognize and penetrate three dimensional tumor
spheroids
The finding that trastuzumab-directed CD16.176V.NK-92 and
HER2-specific CAR T cells likewise target JIMT-1 in monolayer cultures
encouraged us to investigate their anti-tumor efficacy in three-dimen-
sional cultures with an established extracellular matrix. We treated
JIMT-1 spheroids with 10 μg/ml trastuzumab or Alexa Fluor 488-tras-
tuzumab for 24 h and sectioned them to visualize HER2 and CD44
expression (Fig. 2A). Upon staining the sections, both Alexa Fluor 488-
trastuzumab (Fig. 2A, column 2) and the Alexa Fluor 647-anti-CD44
antibody (Fig. 2A, columns 2–4) showed strong specific signals. In
contrast, Alexa Fluor 488-trastuzumab added to intact spheroids as a
treatment could not penetrate their three-dimensional structure
(Fig. 2A, column 3). Incubation of spheroids with unconjugated tras-
tuzumab and post-staining their sections with Alexa Fluor 488 anti-
human IgG revealed a similarly low penetration of unlabeled trastu-
zumab as that of Alexa Fluor 488-trastuzumab into spheroids, excluding
the antibody bound fluorescent dyes as the cause of low penetration.
(Fig. 2A, column 4).
To explore whether spheroids are accessible to antibody and CAR T
cell treatment, spheroids were cocultured with CD16.176V.NK-92 cells
in the presence or absence of trastuzumab or with HER2-specific CAR T
cells. Using confocal microscopy [19], we visualized (Fig. 2B) and
analyzed (Fig. 2D and E) tumor cell killing indicated by incorporation
of propidium iodide (PI) and quantified cell death by integrating PI
fluorescence intensity (Fig. 2C). Both HER2-CAR T cells and trastu-
zumab bound CD16.176V.NK-92 cells showed substantial cytolytic ac-
tivity in the peripheral zone of spheroids (Fig. 2B and D). However,
CAR T cells penetrated far more efficiently into, and killed target cells
in the inner spheroid core, than trastuzumab-guidedCD16.176V.NK-
92 cells (p < 0.001) (Fig. 2E).
3.3. HER2-CAR T cells eliminate HER2 positive tumor xenografts in vivo
To investigate whether the different tissue penetration capacities
result in different efficacies in tumor elimination in vivo, we established
subcutaneous HER2+ MDA-HER2.ffLUC and JIMT-1 xenografts in NSG
mice; HER2-negative MDA.ffLUC cells served as control (Fig. 3A). To
test the in vivo cytolytic function of CD16.176V.NK-92 cells in the
presence or absence of trastuzumab, 5 × 106 CD16.176V.NK-92 cells
and trastuzumab were simultaneously administered starting from the
day of tumor cell inoculation. We found that simultaneous adminis-
tration of trastuzumab plus CD16.176V.NK-92 cells to trastuzumab
resistant MDA-HER2.ffLUC and JIMT-1 cells yielded only partial im-
provement in overall survival (Fig. 3C and D right panels) by somewhat
delaying but not preventing tumor outgrowth from (p < 0.001; Fig. 3C
and D left panels). JIMT-1 tumors treated with trastuzumab were de-
layed in growth with improved overall survival (p < 0.001; Fig. 3D),
likely due to residual macrophage activity in those mice (Suppl. Fig. 4A
and 4B), however, the tumors eventually grew out.
In contrast to the repetitive treatment with trastuzumab and
CD16.176V.NK-92 cells, HER2-CAR T cells were applied in a single dose
of 5 × 106 i.v. on day 14 post transplantation (Fig. 3A). We observed
complete and long-lasting tumor regression of MDA-HER2.ffLUC and
JIMT-1 tumors as opposed to all other treatments (p < 0.001; Fig. 3B, C
and 3D). CAR T cells did not show anti-tumor activity against HER2-
negative MDA.ffLUC tumors confirming the lack of allogeneic tumor
recognition (p > 0.05; Suppl. Fig. 5A and 5B).
3.4. HER2-CAR T cells infiltrate HER2 positive xenografts
In animals treated with HER2-CAR T cells, higher number of in-
filtrating effector cells were localized in tumor sections than in animals
treated with CD16.176V.NK-92 + trastuzumab, even though these
animals have received two rounds of NK cell injections prior to tissue
sectioning (Fig. 4A, B and 4C). We confirmed that the majority of tumor
infiltrating lymphocytes are CD8 positive cytotoxic T cells (Suppl.
Fig. 6) and that these cells are most likely of effector memory (EM)
phenotype (CCR7 - CD45RA double negative, data not shown). This
demonstrates that HER2-specific CAR T cells have the ability to pene-
trate trastuzumab resistant xenografts. In contrast, we did not detect
HER2-CAR T cells in the absence of HER2+ cancer cells (Fig. 4A and B).
In the MDA-HER2.ffLUC group the rapid cytolytic effect of HER2-CAR T
cells did not allow the excision of a tumor.
4. Discussion
HER2-targeted antibodies have been successful in treatment of
HER2-positive breast cancer [1], however, a great percentage of pa-
tients still fail to respond to therapy despite persistent antigen expres-
sion [3]. Overexpression of ECM components such as MUC4 or CD44/
hyaluronan forms a steric barrier that masks HER2 antigen and inhibits
recognition [5–7]. HER2-redirected CAR T cells have shown great po-
tential to eliminate HER2+ trastuzumab sensitive tumor cell lines
(SKBR3 and BT474) in pre-clinical models [13,15] or cure trastuzumab
naïve patients in clinical trials [16,17], however we still have no evi-
dence about their anti-tumor function in trastuzumab resistant tumors.
In this study, we aimed to challenge trastuzumab derived HER2-specific
CAR T cells with trastuzumab resistant tumor cells starting with cells
grown in monolayer cultures, progressing to in vitro three dimensional
spheroids, and reaching the highest tissue complexity with in vivo xe-
nografts.
First, we demonstrated that trastuzumab-redirected CD16.176V.NK-
92 and HER2-CAR T cells recognize and specifically kill HER2+ target
cells in monolayer cultures. This observation is consistent with our
previous findings that trastuzumab binds to its targets and induces
ADCC if the ECM is under-developed [9,10].
Next, we investigated whether trastuzumab-directed
CD16.176V.NK-92 and HER2-CAR T cells are likewise efficacious in
three-dimensional cultures with an established extracellular matrix
[25]. To obtain this goal we established trastuzumab-resistant JIMT-1
spheriods and confirmed the well-developed ECM by confocal micro-
scopy. In correlation with our previous results [5,9,10] overexpression
of CD44/hyaluronan resulted in reduced binding of trastuzumab to
HER2 in JIMT-1 spheroids and consequentially limited the penetration
of CD16.176V.NK-92 cells. In contrast, HER2-specific CAR T cells could
penetrate into the spheroid cores and induced potent anti-tumor re-
sponse, as judged by propidium iodide incorporation [19].
While the lack of penetration of antibodies into tumors with a
massive ECM could in itself limit the antibody-dependent persistence of
NK cells in the tumor, we also need to highlight that the specificity,
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sensitivity and dynamics of NK cell mediated anti-tumor reactions are
much less studied than those of T cells. NK cells as innate immune cells
are one of the first responders at the sites of infection, are therefore
much quicker than CD8+ T cells in establishing a robust response [26].
However, a recent publication suggests that NK cells interact with the
extracellular matrix that suppresses their anti-tumor response [27].
At the same time, several publications suggest that stimulation
through the T cell receptor complex affects cell migration in response to
chemokines, highlighting an interaction between the TCR and chemo-
kine receptors [28]. Antigen recognition and consequential differ-
entiation into effector memory phenotype downregulates CD62L and
CCR7 expression to limit T cell homing to the lymph nodes and upre-
gulates several molecules that enable them to migrate into the inflamed
tumor environment, among them E- and P-selectins, and chemokine
receptors such as CXCR3 which binds CXCL9 and CXCL10 [29]. Such
regulatory mechanisms could well contribute to the enhanced persis-
tence and cytolytic activity of CAR T cells in tumors.
In the preclinical setting, JIMT-1 and MDA-HER2 tumors growing in
NSG mice were used to demonstrate in vivo the anti-tumor effects of
trastuzumab-redirected CD16.176V.NK-92 and HER2-CAR T cells. To
test the in vivo cytolytic function of CD16.176V.NK-92 cells in the
presence or absence of trastuzumab we injected 5 × 106 cells i.v. bi-
weekly and simultaneously administered 100 μg trastuzumab twice-
weekly starting from the day of tumor cell inoculation. Although this
treatment was previously shown to effectively induce the total regres-
sion of established trastuzumab sensitive BT474 xenografts [30], it
could not prevent the outgrowth of trastuzumab resistant MDA-
HER2.ffLUC and JIMT-1 tumors in our pre-clinical model even when
treatment started together with tumor inoculation. These results ob-
tained with human tumor cells and human NK cells in NSG mice re-
capitulate our previous finding where trastuzumab treatment delayed
but did not prevent the outgrowth of JIMT-1 xenografts in SCID mice
having their own mouse NK cells if treatment was started at the time of
tumor inoculation [9–11].
In contrast to the repetitive treatment with trastuzumab and
CD16.176V.NK-92 cells, a single i.v. dose of 5 × 106 HER2-CAR T cells
on day 14 post tumor inoculation resulted in complete and long-lasting
tumor regression of MDA-HER2.ffLUC and JIMT-1 tumors, even though
at the time of treatment tumors were 250 mm3 in size and had a well-
stablished ECM. Similar to the case of in vitro grown spheroids, HER2-
specific CAR T cells also penetrated trastuzumab resistant xenografts in
vivo. However, no penetration and tumor lysis was seen in HER2-ne-
gative MDA.ffLUC control xenografts, which suggests that active inva-
sion of and accumulation in the tumor of HER2-CAR T cells is driven by
Fig. 2. Confocal microscopic analysis of HER2-CAR T cell and NK cell mediated killing of tumor spheroids.
(A) Representative frozen sections of JIMT-1 spheroids treated with 10 μg/ml trastuzumab or Alexa Fluor 488 conjugated trastuzumab (A488-TRAST) and controls.
Sections were post-stained with 10 μg/ml Alexa Fluor 647-anti-CD44 to reveal CD44 (A647-α-CD44; columns 2–4, red, first row), Alexa Fluor 488-anti-human IgG
(A488-α-HuIg) to detect trastuzumab bound to HER2 (columns 1/negative control/and 4, green, second row) or Alexa Fluor 488-trastuzumab to directly visualize
HER2 (A488-TRAST; column 2, green, second row), as well as DAPI for DNA (blue). (B) Representative images (at 24 h) for detection of cytolytic activity of
CD16.176V.NK-92 or T cells against JIMT-1 spheroids. Dead cells were visualized by PI uptake (red). (C) Schematic representation of the optical sections through the
spheroid. (D) Tumor cell killing was determined as integrated pixel intensity (PI channel; intensity × area). Each well contained one spheroid and 200,000 effector
cells. The histograms represent PI incorporation in the entire (D) spheroid and in the CORE region (E) of the spheroid in the presence of media, NT T cells,
CD16.176V.NK-92 cells, 10 μg/ml trastuzumab, CD16.176V.NK-92 cells plus 10 μg/ml trastuzumab, and HER2-CAR T cells. Histograms show mean ± SD (n = 3;
***p < 0.001).
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specific antigen recognition.
Taken together, we here demonstrate that established clinic-derived
and in vitro generated trastuzumab-resistant tumors can be efficiently
eliminated by HER2-CAR T cells but not by treatment with trastuzumab
plus CD16.176V.NK-92 cells although both recognize the same HER2
epitope. Our previous data indicate that ECM components cause tras-
tuzumab therapy resistance by steric hindrance of antigen recognition,
which could also mitigate the success of emerging antibody-drug con-
jugate (ADC) therapies. CAR T cells obviously overcome the ECM bar-
rier as trastuzumab resistant spheroids and established xenograft tu-
mors are penetrated and destroyed by CAR T cells. We posit that clinical
application of trastuzumab derived HER2-specific CAR T cells can be an
option for the treatment of trastuzumab resistant tumors.
Author contributions
G.V. and A.Sz. designed the study. T.G. and A.Sz. performed ex-
periments. B.Zs. provided JIMT-1 spheroids. V.Sz. performed ELISA
expreiments. Z.E and H.A. provided reagents. All authors contributed to
data analysis and manuscript preparation.
Funding
We acknowledge the financial support from OTKA K119690 and
FK132773 (National Research Development and Innovation Office,
Hungary), GINOP-2.3.2-15-2016-00044 (co-financed by the European
Union and the European Regional Development Fund), and Deutsche
Fig. 3. HER2-CAR T cells eliminate HER2 positive tumor xenografts in vivo.
Mice were injected s.c. with 3 × 106 MDA-HER2.ffLUC or JIMT-1 cells. Mice treated from the day of tumor inoculation received 100 μl PBS i.p. twice weekly
(untreated, n = 10), or 100 μg trastuzumab in 100 μl PBS i.p. twice weekly (trastuzumab, n = 10, green), or 5 × 106 CD16.176V.NK-92 cells i.v. biweekly
(CD16.176V.NK-92, n = 10, orange) or trastuzumab i.p. twice weekly plusCD16.176V.NK-92 cells i.v. biweekly (CD16.176V.NK-92+trastuzumab, n = 10, blue).
CAR T treated mice received on day 14 (arrow) a single i.v. dose of 5 × 106 NT T cells (NT T cell, n = 10, black) or HER2-CAR T cells (HER2-CAR T cell, n = 10, red).
Tumor growth was followed by bioluminescence imaging (MDA-HER2.ffLUC) or by caliper measurements (JIMT-1, volume derived as the product of the length,
width and height). (A) Outline of the treatment schedule. (B) Representative images of MDA-HER2.ffLUC injected animals. (C left panel) Quantitative biolumi-
nescence imaging data of MDA-HER2.ffLUC xenografts (radiance = photons/s/cm2/sr; HER2-CAR vs. all other treatments: ***p < 0.001; CD16.176V.NK-92 +
trastuzumab vs. all non-HER2-CAR groups ***p < 0.001). (C right panel) Kaplan-Meier survival curve (HER2-CAR vs. all other treatments: ***p < 0.001). (D left
panel) Tumor volume of JIMT-1 tumors (mm3; HER2-CAR vs. all other treatments: ***p < 0.001; Trastuzumab±CD16.176V.NK-92 groups vs. all non-HER2-CAR
groups ***p < 0.001). (D right panel) Kaplan-Meier survival curve (HER2-CAR vs. all other treatments: ***p < 0.001; Trastuzumab±CD16.176V.NK-92 groups vs.
all non-HER2-CAR groups ***p < 0.001). Histograms represent mean ± SD.
Fig. 4. Effector cell infiltration of HER2 positive tumors.
Frozen sections of excised tumors were fluorescently labeled for HER2 (green), T cells (CD3e; red) or NK cells (CD56, red), and DNA (DAPI, blue). (A) Sections from
HER2- control MDA.ffLUC tumors (left column) and HER2+ JIMT-1 tumors (right column) treated with HER2-CAR T cells. (B) Sections from HER2- control
MDA.ffLUC tumors (left column), HER2+ MDA-HER2.ffLUC tumors (middle column) and JIMT-1 tumors (right column) treated with CD16.176V.NK-92 cells plus
trastuzumab are shown. (C) Effector cell penetration was quantitatively analyzed by counting CD3e+ and CD56+ nucleated cells in randomly selected 0.05 mm2
areas of the section. The histograms represent mean ± SD of effector cells/field (n = 6). In mice with MDA-HER2.ffLUC tumors the rapid cytolytic effect by HER2-
CAR T cells did not allow the excision of a tumor (N/A label). ***p < 0.001.
Á. Szöőr, et al. Cancer Letters 484 (2020) 1–8
7
Krebshilfe, Bonn, FRG. A.Sz. was supported by the János Bolyai
Research Scholarship of the Hungarian Academy of Sciences and by the
UNKP-19- 4-DE-167 New National Excellence Program of the Ministry
for Innovation and Technology.
Declaration of competing interest
The authors declare no conflicts of interest.
Acknowledgements
CD16.176V.NK-92 cells were obtained from Dr. Kerry S. Campbell
(Fox Chase Cancer Center, Philadelphia, PA, USA), are protected by
patents or pending patents worldwide, and were licensed by Nantkwest,
Inc. (www.nantkwest.com). We thank Dr. Kerry S. Campbell and Dr.
Barry J. Simon (Nantkwest, Inc.) for stimulating discussion. We are
indebted to Prof. László Virág (Department of Medical Chemistry,
University of Debrecen) for access to the ECIS Zθ system and to Dr.
Péter Gogolák for providing APC-conjugated F4/80 antibodies.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.canlet.2020.04.008.
Abbreviations
ADCC Antibody-dependent cell-mediated cytotoxicity
CAR Chimeric Antigen Receptor
CD16 Fc gamma receptor type III
CD44 Receptor for hyaluronic acid
ECM Extracellular matrix
EM Effector memory
ffLUC Firefly luciferase
GFP Green fluorescent protein
HER2 Human epidermal growth factor receptor 2
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